

Index

- acrolein, 132
acytoplasmic ring, 109
adhesion, early, 101, 110
air quality, 130–2
Alpha/European Society of
 Human Reproduction and
 Embryology (ESHRE) consensus,
 16, 104
aneuploidy. *See also* chromosomal
 abnormalities
 mechanisms, 70
 morphokinetic markers, 120–1,
 124–5, 147
 morphological features, 6
annotation, 15–17, 117
 EmbryoScope system, 17, 28
 Primo Vision system, 44
assisted hatching, 7

blastocyst formation, 21–3
 anomalies, 172
 failed, 21
 in group culture, 38
 prediction, 62, 66, 119, 123
blastocysts
 artificial shrinkage of blastocoel, 7
 collapse, 121–2
 cryopreservation, 7–8
 cytoplasmic strings, 26
 degenerating, 21
 elimination of cells, 172
 expansion and collapse (pulsing),
 25–6, 49, 113
 hatching. *See* hatching
 morphological assessment, 6,
 112–17
 scoring system, 115–17
blastomeres
 biopsy, 5
 exclusion at morula stage, 25
 failure of one to develop, at two-cell
 stage, 23
 irregular shape, 109
 number on day 2/day 3, 92–3,
 105
 polarization, 99
 size and symmetry, 96–8, 107,
 119–22
bovine embryos, 38

cell division. *See also* cleavage
 annotations, 117
 charts, 17–18
 rate on day 2/day 3, 92–3, 105
cell number on day 2/day 3, 92–3, 105
centrally located granular cytoplasm
 (CLCG), oocytes, 78, 87
chromosomal abnormalities. *See also*
 aneuploidy
 direct unequal cleavages and, 147
 elimination of blastomeres with,
 172
 morphological features, 6, 98
cleavage. *See also* cell division
 abnormal phenotype, 70, 74
 abnormal, Eeva Test, 65, 67
 anomalies, 169–71
 direct. *See* direct cleavage
 early. *See* early cleavage
 failure, one blastomere at two-cell
 stage, 23
 first. *See* first cleavage
 reverse, 25, 28, 171
 uneven, 23, 49, 119–22
 wobbling effect, 23
cleavage-stage embryos, 104–11
 arrested development, 22
 elimination of unsuitable, 6
 grading of quality, 91–2, 111
 standard morphological assessment,
 90–101, 104–10
communication, patient, 28
compaction, 111–12
 early, 101, 110
 partial, 112
 reverse, 171–2
controlled ovarian hyperstimulation
 (COH), 1–2
counseling app, EmbryoScope, 14, 28
cryopreservation, 7–8
culture media, 5, 130
culture, in vitro, 4–5, *See also* group
 culture
 Eeva system, 57
 EmbryoScope system, 14–15
 Primo Vision system, 38
cumulus cells
 evaluation of quality, 6
 removal prior to ICSI, 3

cumulus–oocyte complexes
 (COC). *See also* oocytes
 assessment of quality, 2
 blood clots, 2
 conventional IVF, 2
 harvesting, 2
cytokinesis. *See* cleavage
cytoplasmic granulation. *See*
 granularity, cytoplasmic
cytoplasmic strings, 26
cytoplasmic waves, 19

diploid oocytes, 6
direct (unequal) cleavage (DUC), 96,
 146–7, 169–70
 chromosomal abnormalities, 147
 clinical outcome, 120–2
 EmbryoScope system, 21–4, 28
donor egg recipient (DER) transfers,
 156–7

early cleavage, 49, 90
 laboratory quality assessment, 129
early pregnancy loss, 29, 123
Eeva Dish, 57
Eeva Scope, 55
Eeva Scope Screen, 58
Eeva Station, 58
Eeva Test, 51–73
 case examples, 62–5, 67
 clinical application, 59–65
 clinical validation, 60–2, 123
 consistency of results, 62, 68–9
 hardware, 52, 55–7
 ongoing research, 65–72
 practical use, 57–60, 63
 software, 52–4
electromagnetic radiation, 32, 39
embryo biopsy, 5
embryo cryopreservation, 7–8
embryo morphokinetics.
 See morphokinetics, embryo
embryo morphology, 6, 104–17
 day 2 (D2) and day 3 (D3)
 parameters, 90–101, 104–10
dynamics, kinetic markers,
 121–2
Eeva Test vs. standard, 62
Primo Vision system, 43–7

Index

- scoring. *See* scoring systems
 time-lapse vs. standard, 101
 embryo quality, 104–25
 blastocyst stage, 112–17
 cleavage stage (day 2 and day 3), 90–101, 104–10
 morphokinetic assessment, 117–25
 morula stage, 111–12
 oocyte morphology and, 84–5
 scoring. *See* scoring systems
 standard morphological assessment, 104–17
 embryo selection, 5–6
 Eeva Test, 59–65
 EmbryoScope system, 28–9, 146–8
 morphokinetic models, 122–5, 160–2
 Primo Vision system, 43–7
 embryo transfer, 6–7
 embryo utilization rate, 129
 EmbryoScope time-lapse system, 11–29
 applications, 17–27
 benefits, 27–9
 clinical outcome data, 28–9, 147–57
 counseling app, 14, 28
 features, 11–14
 history of development, 11
 incubator, 11
 server, 13
 setup and procedure, 14–17
 testing and validation, 144–6
 EmbryoSlide culture dish, 11–12, 14–15
 EmbryoViewer software, 12, 15–17, 28
 annotation strategies, 15–17
 time-lapse parameters, 15
- fair-quality embryos
 blastocyst stage, 116
 cleavage stage, 91, 111
 morula stage, 112
- fertilization
 anomalies, 165–9
 in vitro (IVF), 2–3
- fertilization rate
 laboratory quality assessment, 128
 oocyte morphology and, 84–5
- fertilized eggs. *See* zygotes
- first cleavage, 23, 90
 abnormal phenotype, 70, 73
 early. *See* early cleavage
 into three or more cells, 24, 96, 146, 169–70
 kinetic markers, 119
 without pronucleus formation, 169, 169
- Food and Drug Administration (FDA), 11, 51–2
- four-cell rate on day 2, laboratory
 quality assessment, 129–30
 fragment resorption, 106, 121
 fragmentation, 49, 93–6, 105–6
 acceptable morphology after, 96
 aneuploidy development, 70
 blastocyst stage, 117
 type IV, 105
- giant oocytes, 6
 good-quality embryos
 blastocyst stage, 115–16
 cleavage stage, 91, 111
 morula stage, 112
- grading systems. *See* scoring systems
 granularity, cytoplasmic
 embryos, 101
 oocytes, 78, 87
- group culture, 5
 quality control testing, 141
 time-lapse systems, 14–15, 38, 57
- hatching, 26, 113, 117
 assisted, 7
 blastocyst pulsing, 23–6
- hyaluronidase, 3
- ICSI. *See* intracytoplasmic sperm injection
- image analysis, Eeva Test, 54, 58
- implantation rate (IR)
 Eeva Test results, 66–70
 EmbryoScope outcome data, 28–9, 148–9
 ICSI vs. insemination, 153
 known implantation data (KID) concept, 18
 laboratory quality assessment, 128
 morphokinetic models and, 29, 124–5
 morphokinetic parameters and, 53, 119–20
 multinucleated embryos, 29, 98, 122
- in vitro fertilization (IVF), 2–3
- inner cell mass (ICM), 113–14
 scoring of quality, 116
 small, 114
- insemination, EmbryoScope outcome data, 151–6
- intracytoplasmic sperm injection (ICSI), 1, 3–4
 EmbryoScope outcome data, 151–6
 incorrect, 20
- IVF. *See* in vitro fertilization
- key performance indicators (KPIs), 128–9
- KIDScore decision support tool, 28
- known implantation data (KID), 18
- laboratory
 benefits of EmbryoScope system, 27
 quality management, 128–42
 workflow, Eeva Test, 58
- laser-assisted sperm immobilization, 3–4, 4
- light exposure, 32–3, 35
- live birth rate
 EmbryoScope outcome data, 148–9, 149
 ICSI vs. insemination, 152
 morphokinetic markers and, 119
- luteal phase support, 7
- microsurgical epididymal sperm aspiration (MESA), 1
- mineral oil, toxicity testing, 133–41
- miscarriage rate, 149
- morphokinetic models
 embryo selection, 122–5, 160–2
 quality control testing, 133–5
- morphokinetic parameters, 52–3, 117–22
 calculated variables, 118–19
 different cell stages, 119–21
 Eeva Test system, 52–4, 58–61
 EmbryoScope system, 15, 19
 morphology dynamics, 121–2
 pronuclear dynamics and first cytokinesis, 119
- morphokinetics, embryo, 6, 15, 117–25
 annotation. *See* annotation
 clinical benefits, 28–9, 47–9
 EmbryoScope system, 17–19
 oocyte morphology and, 83–7
 parameters. *See* morphokinetic parameters
 Primo Vision system, 43–7
 role in clinical embryology, 158–62
- morphology. *See* embryo morphology; oocyte morphology
- morula
 exclusion of blastomeres, 25
 morphological classification, 111–12
- mouse embryo assay (MEA), 132–5
- multinucleation, 29, 98–9, 106–7, 122
- necrotic bodies, 81, 89
- non-viable embryos. *See* poor-quality embryos
- nuclei, visualization of, 98–9
- nucleolar precursor bodies (NPBs), 48
- oocyte morphology, 6, 77–87
 embryo morphokinetics and, 83–7
 embryo quality and, 84–5
 fertilization ability and, 84–5
 phenotypes, 78–82

Index

- oocytes. *See also* cumulus–oocyte complexes
 denudation prior to ICSI, 3
 ICSI procedure, 4
 retrieval, 2
 optimal embryos. *See* good-quality embryos
 ovarian hyperstimulation, controlled (COH), 1–2
 ovarian puncture, transvaginal, 1–2
 oxygen concentration, reduced, 144
- partial zona dissection (PZD), 1
 perivitelline space
 cellular debris in, 82
 large (LPS), 81
 pitting, 110
 polar body (PB)
 biopsy, 5, 27
 dysmorphisms of first, 82, 87
 extrusion of second, 20, 165
 transient emission of a third, 165–6
 poor-quality embryos
 blastocyst stage, 116
 cleavage stage, 91, 111
 morula stage, 112
 pregnancy rates
 Eeva Test results, 66–9
 EmbryoScope outcomes, 148–50, 154
 ICSI vs. insemination, 153
 Meseguer *et al.* morphokinetic algorithm and, 29, 122–3
 multinucleated embryos, 29
 Primo Vision time-lapse system, 31–49
 concept, 32–4
 controlling unit, 34, 39
 description, 34–47
 digital microscope, 34–5
 embryo culture dish, 34–9
 maintenance, 47
 rationale, 31–2
 setup, 47
 software, 39–48
- pronuclei (PN)
 breakdown and reappearance, 167, 167–8
 breakdown asynchrony, 168–9
 first cleavage in absence of, 169
 formation, 20
 fusion of two, 21
 kinetic markers, 119, 121
 late formation of a third, 166–7
 morphological evaluation, 6
 scoring, 48
 protein, quality control testing, 141
- quality control testing, 133–41
 quality management, IVF laboratory, 128–42
 clinical examples, 129–32
 rationale for using time-lapse, 128–9
- refractile bodies, 80, 87
 reverse cleavage, 25, 28, 171
 reverse compaction, 171–2
 Rhesus macaques, 71–2
- scoring systems, 101
 blastocysts, 115–17
 cleavage-stage embryos, 91–2, 111
 morula-stage embryos, 112
- semen
 processing for IVF, 2
 unprocessed, 3
 shear stress, 31–3
 smooth endoplasmic reticulum (SER)
 clusters, 78–9
 clinical significance, 6, 87
 formation and disappearance, 21–2
 somatic cell nuclear transfer (SCNT), 32
- sperm(atozoa)
 ICSI procedure, 4
 immobilization, 3–4
 motility, 4
 role in embryo development, 71–2
- sterilization, time-lapse equipment, 33
 stress, 31–2
 suboptimal embryos. *See* fair quality embryos
 subzonal injection (SUZI), 1
 syngamy phenotype, abnormal, 70
- testicular sperm extraction (TESE), 1
 time from two-to-three cell (P2), 52–3, 54, 59, 60–1
 time from three-to-four cell (P3), 52–3, 54, 59, 60–1
 time-lapse markers. *See* morphokinetic parameters
 trophectoderm (TE)
 biopsy, 5–6
 morphological assessment, 114
 scoring of quality, 116
- two-cell embryos
 failure of one cell to develop, 23
 formation. *See* first cleavage
 multinucleation, 29, 98–9, 106
 reverse cleavage, 171
- vacuoles
 within embryos, 99, 109, 117
 within oocytes, 79, 87
- vitrification, 7–8
 volatile organic compounds (VOC), 32, 130, 132, 134
- wobbling effect, first cleavage, 23
- zona pellucida, 100, 109
 blastocyst stage and hatching, 26, 113
 dysmorphisms, 81, 83, 85–6, 109–10
 zona-free embryos, group culture, 36–7
- zygotes
 cleavage. *See* first cleavage
 cryopreservation, 7–8
 in vitro culture, 4–5
 morphological evaluation, 6